

INNODIA screening for early-stage type 1 diabetes: Insights from Polish first-degree relatives of T1D patients (2015–2023, EU115797)

Magdalena Małachowska^{1,A–D}, Kamil Kosiorowski^{1,2,A–D}, Paulina Pokrywka^{1,A–D}, Eliza Skąła-Zamorowska^{3,A–F}, Ewa Rusak^{3,A–F}, Halla Kamińska^{3,A–F}, Sebastian Jacek Seget^{3,A–F}, Aleksandra Pyziak-Skupień^{4,A–F}, Grażyna Deja^{3,A–F}, Przemysława Jarosz-Chobot^{3,A–F}

¹ Students' Scientific Association at the Department of Children's Diabetology and Lifestyle Medicine, Medical University of Silesia, Katowice, Poland

² College of Interdisciplinary Studies at the University of Silesia in Katowice, Poland

³ Department of Children's Diabetology and Lifestyle Medicine, Medical University of Silesia, Katowice, Poland

⁴ Department of Children's Diabetology and Pediatrics, Upper Silesian Centre for Child Health, Katowice, Poland

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation;

D – writing the article; E – critical revision of the article; F – final approval of the article

Advances in Clinical and Experimental Medicine, ISSN 1899–5276 (print), ISSN 2451–2680 (online)

Adv Clin Exp Med. 2026;35(4):599–609

Address for correspondence

Magdalena Małachowska
E-mail: mmalachowska25@gmail.com

Funding sources

INNODIA has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115797. This Joint Undertaking is supported by the European Union's Horizon 2020 research and innovation program, EFPIA, JDRF, and The Leona M. and Harry B. Helmsley Charitable Trust.

Conflict of interest

None declared

Received on May 18, 2025

Reviewed on July 28, 2025

Accepted on July 31, 2025

Published online on January 13, 2026

Cite as

Małachowska M, Kosiorowski K, Pokrywka P, et al. INNODIA screening for early stage type 1 diabetes: Insights from Polish first-degree relatives of T1D patients (2015–2023, EU115797). *Adv Clin Exp Med.* 2026;35(4):599–609. doi:10.17219/acem/208837

DOI

10.17219/acem/208837

Copyright

Copyright by Author(s)

This is an article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) (<https://creativecommons.org/licenses/by/3.0/>)

Abstract

Background. Early identification of individuals at increased risk for type 1 diabetes (T1D) is essential to prevent diabetic ketoacidosis (DKA) at onset and to facilitate the development of disease-modifying therapies. The INNODIA EU115797 project (2015–2023) conducted a Europe-wide screening of individuals with recent-onset T1D (<6 weeks) and their first-degree relatives (aged 1–45 years).

Objectives. To evaluate the risk of T1D development among first-degree relatives of individuals with T1D, based on data from the Polish INNODIA center at the Medical University of Silesia in Katowice, Poland.

Materials and methods. Data on the incidence of autoantibodies were obtained from the INNODIA project platform. The analysis included first-degree relatives of individuals with T1D, aged 1–45 years, who met the inclusion criteria and were recruited at the Polish center. Samples were collected at the Medical University of Silesia in accordance with the INNODIA protocol. Participants were stratified based on the number of autoantibodies detected (1 or ≥2). The analysis considered age, sex, prevalence of specific autoantibodies (GAD65, IAA, IA-2A, ZnT8), and familial relationship.

Results. Among 817 screened individuals, 65 (7.96%) tested positive for autoantibodies (AA): 48 (5.88%) had 1AA and 17 (2.08%) had ≥2AA. The highest prevalence was observed in the 10–23-year age group (27.7%, 18/65). In this subgroup, 11.04% (18/163) were autoantibody-positive, whereas prevalence in other age groups (1–9, 24–36, 37–40, and 41–45 years) ranged from 5.98% to 8.97%. GAD65 (5.51%) and IAA (3.43%) were the most frequent autoantibodies. Individuals with 1AA were predominantly parents (32/48; 66.7%), while ≥2AA were more common among siblings (13/17; 72.2%). During follow-up, 2 participants progressed to stage 3 T1D.

Conclusions. In the Polish cohort of the INNODIA study, autoantibodies were detected in 7.96% of first-degree relatives of individuals with T1D. Early screening is crucial for accurate risk stratification, guiding the development of therapeutic interventions and reducing the risk of severe complications at disease onset.

Key words: autoantibodies, diabetes mellitus type 1/diagnosis and immunology, mass screening/methods, autoimmune diseases/diagnosis, autoimmune diabetes mellitus

Acknowledgements

We would like to express our sincere gratitude to the INNODIA investigators and participants of the INNODIA program for their courage and for making this study possible. Special thanks go to Hanna Szczudło M.Sc., Urszula Bielec M.Sc., Lilianna Gremłowska M.Sc., Agnieszka Straszewska M.Sc., and Piotr Kusa M.Sc. for their essential roles in ensuring the smooth organization and success of the program at the Polish site. We also extend our gratitude to all the associates, researchers, healthcare professionals, and collaborators whose collective efforts made this work possible.

Highlights

- Polish INNODIA data align with European trends: Autoantibody prevalence in first-degree relatives of type 1 diabetes (T1D) patients mirrors findings from other European cohorts.
- 7.96% of first-degree relatives tested positive for T1D-related autoantibodies: GAD65 and IAA were the most frequently detected markers across all subgroups.
- Highest autoantibody positivity in youth and siblings: Rates peaked in the 10–23 age group and among siblings of individuals with T1D.
- Progression without DKA observed: Two children advanced to stage 3 T1D without developing diabetic ketoacidosis, underscoring benefits of early monitoring.
- Early recognition and supportive care are critical: Integrating prompt symptom identification into protocols can improve outcomes in early-stage T1D.

Background

Type 1 diabetes (T1D) is the most common type of diabetes in the European pediatric population, with nearly 129,000 new diagnoses each year globally in children and adolescents under 20 years of age.^{1,2} According to the T1D Index, the estimated number of people living with T1D in 2024 was 9.4 million, and with the continued rise in its incidence, this number is expected to reach 16.4 million by 2040 ((Type 1 Diabetes Index; <https://www.t1dindex.org>).

Thanks to ongoing T1D research, remarkable progress has been made in staging the early phases of the disease and refining its definitions. It is now well established that autoantibodies, which serve as markers of T-cell-mediated β -cell destruction, may appear years before the clinical onset of T1D. Identification of T1D-related autoantibodies – such as GAD65 (glutamic acid decarboxylase), IAA (insulin autoantibody), IA-2A (islet antigen-2 antibody), and ZnT8 (zinc transporter-8 antibody) – in combination with glucose metabolism monitoring enables classification of preclinical stages of T1D: stage 1 (≥ 2 autoantibodies and normoglycemia), stage 2 (≥ 2 autoantibodies and dysglycemia) and stage 3 (≥ 2 autoantibodies and clinical onset).^{3–6} The International Society for Pediatric and Adolescent Diabetes (ISPAD) 2024 Guidelines provide more detailed subdivision of these stages, reflecting advances in understanding of the disease.⁵

In recent years, initiatives to identify individuals in the early stages of T1D have laid the foundation for ongoing screening efforts to reduce the incidence of diabetic ketoacidosis (DKA) at T1D onset, as well as to minimize short and long-term morbidity, mortality, prolonged hospitalization, weight loss, and psychological burden associated with T1D onset.⁷ These endeavors also provide participants with the opportunity to enroll in clinical trials investigating disease-modifying therapies aimed at delaying the onset of T1D. Islet autoantibody testing has proven to be an effective method for detecting early-stage T1D and may be preferred over genetic testing due to lower participant

dropout rates and its predictive value in stratifying the rate of progression to stage 3 T1D once autoantibodies are developed.⁵ Moreover, genetic risk is frequently perceived as abstract and difficult for parents to fully understand and accept.⁸ In accordance with the most recent ISPAD guidelines, population-based screening for T1D is optimally performed between 3 and 5 years of age, with maximal sensitivity achieved by 2 examinations at 2 and 6 years of age.⁵ When screening is deferred until adolescence, the preferred time points are 10 and 14 years of age.⁵ However, it should be emphasized that despite the ongoing efforts to integrate T1D screening into national healthcare systems, still only a minority of countries currently maintain nationwide programs. In Poland, the majority of children who present with – or are likely to develop – stage 3 T1D have not undergone prior T1D screening. Therefore, if the standard, age-based screening windows cannot be met, it is reasonable to offer T1D screening independently of a child's age.

In 2015 the INNODIA (now an international non-profit organization, formerly a European-based public-private partnership) launched the project (EU115797) titled Translational Approaches to Disease-Modifying Therapy of Type 1 Diabetes: An Innovative Approach Towards Understanding and Arresting Type 1 Diabetes.⁹ The study protocol was approved by the Bioethics Committee of the Medical University of Silesia (Katowice, Poland; approval No. KNW/0022/KB1/25/I/17 issued on May 16, 2017). As the largest program of its kind at the time, this European-wide initiative conducted a screening of individuals with newly diagnosed T1D (diagnosed less than 6 weeks prior) as well as first-degree relatives of individuals living with T1D. The study ran from November 1, 2015, to October 31, 2023, and included participants from 13 European countries, including Poland with the reference site at the Medical University of Silesia, which became an accredited clinical trial site. The project was carried out under the framework of the Innovative Medicines Initiative – Joint Undertaking (IMI-JU) and involved a global partnership between academic researchers and industrial partners, all working towards combating T1D.⁹

It has been well established that first-degree relatives of individuals with T1D face a markedly higher (up to 15 times) risk of developing T1D than the general population, with the prevalence of T1D in the first-degree relatives equal to 5% by the age of 20, compared to 0.3–0.4% in the general population.^{5,10–12}

Children of mothers with T1D have a 1.3–4% risk of developing the disease, whereas children of fathers with T1D have a higher risk of 6–9%. In siblings of individuals with T1D, the lifetime risk is estimated at approx. 6–7%.^{10–12} Relatives of individuals with T1D should certainly be included in early screening; however, population-wide screening is also warranted, as it is reasonable to state that everyone is at risk of developing T1D. This is supported by evidence showing that approx. 90% of individuals with recent-onset T1D have no known family history of the disease.⁵

Objectives

The aim of this study was to describe and characterize the risk of type T1D development in the Polish population, based on data from the INNODIA screening project, which focused on first-degree relatives of individuals with T1D.

Materials and methods

Between 2018 and 2023, all first-degree relatives (aged 1–45 years) of individuals either newly diagnosed with T1D or already receiving care at the Outpatient Department of Children’s Diabetology and Lifestyle Medicine at the Independent Public Clinical Hospital No. 6 of the Silesian Medical University in Katowice (Upper Silesian Child Health Centre) were invited to participate in the INNODIA study conducted at the Medical University of Silesia.

In addition to serving as an INNODIA clinical site, this center is accredited as a certified SWEET (Better control in Pediatric and Adolescent diabetes: Working to create Centers of Reference) reference center and participates in international projects, including the European Action for the Early Diagnosis of Early Non-Clinical Type 1 Diabetes for Disease Interception (EDENT1FI).¹³




Fig. 1. Allocation of participants to the Unaffected Family Member (UFM) and People at Increased Risk (PIR) groups

To be enrolled, participants were required to meet the inclusion and exclusion criteria outlined in Table 1. Eligible individuals were invited for a screening visit, which included a blood test for the presence of T1D-specific autoantibodies (GADA, IAA, IA-2A, ZnT8A). Three autoantibodies (GADA, IA-2A and ZnT8A) were analyzed at the PEDIA (Pediatric Diabetes Research Group) laboratory at the University of Helsinki, Finland, while IAA was measured using a specific radiobinding assay.¹⁴

If participants tested positive for autoantibodies (AA), they were assigned to either the Unaffected Family Member (UFM) or People at Increased Risk (PIR) group, depending on the year of enrollment. Individuals who were screened up until the July 20, 2022, were assigned to the UFM group. If the screening resulted in at least 1 positive autoantibody, participants continued in the study and followed a specific visit schedule to ensure they received specialized medical care. Consecutively, every patient enrolled in the study after July 20, 2022, was assigned to the PIR group. In this case, further medical care was provided only if the individual was found to have at least 2 autoantibodies present (Fig. 1).

Participants in both the UFM and PIR groups received medical care through regular follow-up visits, which included eligibility screening, medical history review, anthropometric measurements, assessment of glycemic control (oral glucose tolerance test (OGTT) and glycated hemoglobin (HbA1c)), immunological testing, and bio-banking. Detailed schedule for visits and performed tests are presented in the Tables 2,3. If required, any additional tests were performed in order to provide the best possible care following then-current ISPAD guidelines. At the time of the INNODIA study, the clinical site at the Medical University of Silesia was not conducting any kind of trials aimed at people at an early stage of T1D. Therefore, participants were not offered enrolment to the clinical trials but were

Table 1. Inclusion and exclusion criteria for participants in the Unaffected Family Member (UFM) and People at Increased Risk (PIR) groups

Criteria	UFM and PIR
Inclusion	<ul style="list-style-type: none"> • Have given written informed consent to participate. • Aged between 1 year and <45 years. • Have a first-degree relative with T1D (parent, child, full or half siblings) diagnosed at <45 years of age.
Exclusion	<ul style="list-style-type: none"> • The affected first degree relative has type 2 diabetes, monogenic diabetes or diabetes secondary to another medical condition. • Concurrent use of long-term immunosuppressive agents (including oral steroids) or medication likely to confound the interpretation of study results. • Any medical history or clinically relevant abnormality that is deemed by the principal investigator and/or co-investigator to make the participant ineligible for inclusion because of problems in data interpretation or safety concerns. • Participating in an interventional or other drug research which could affect the primary objectives of the study.

Table 2. Schedule of visits for the Unaffected Family Member (UFM) group

Assessments and procedures	Baseline visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7
Time point	0 months*	6 months	12 months	18 months	24 months	36 months	48 months
Inclusion/exclusion	x	x	x	x	x	x	x
Update medical and family history	x	x	x	x	x	x	x
Concomitant medication	x	x	x	x	x	x	x
Height [cm] and weight [kg]	x	x	x	x	x	x	x
Autoantibodies	x	–	x	–	x	x	x
HbA1c	x	x	x	x	x	x	x
PBMC	x	x	x	x	x	x	x
Blood samples for storage	x	x	x	x	x	x	x
Urine (biomarkers)	x	–	x	–	x	x	x
Stool (microbiome)	x	x	x	x	x	x	x
OGTT	x	x	x	x	x	x	x
CGM**	x	x	x	x	x	x	x
Allocation of glucose meter at visit 1	x	–	–	–	–	–	–
Home collection of monthly C-peptide DBS and BG measurements	x	x	x	x	x	x	x
Retention of contact details for all participants at clinical site	–	–	–	–	–	–	x

*Visit to be scheduled ideally within 3 months following receipt of their autoantibody test results. ** If dysglycemia at OGTT.

HbA1c – hemoglobin A1c (%); PBMC – peripheral blood mononuclear cells; OGTT – oral glucose tolerance test; CGM – constant glucose monitoring; DBS – dried blood spot; BG – blood glucose.

Table 3. Schedule of visits for the People at Increased Risk (PIR) group

Assessments and procedures	Baseline visit 1	Visit 2	Visit 3	Visit 4	Visit 5
Time point	0 months*	6 months	12 months	18 months	24 months
Inclusion/exclusion	x	x	x	x	x
Update medical and family history	x	x	x	x	x
Concomitant medication	x	x	x	x	x
Height [cm] and weight [kg]	x	x	x	x	x
Autoantibodies	x	–	x	–	x
HbA1c	x	x	x	x	x
Blood samples for storage	x	x	x	x	x
OGTT	x	x	x	x	x
CGM**	x	x	x	x	x
Retention of contact details for all participants at clinical site	–	–	–	–	x

*Visit to be scheduled ideally within 3 months following receipt of their autoantibody test results. ** If dysglycemia at OGTT.

HbA1c – hemoglobin A1c (%); OGTT – oral glucose tolerance test; CGM – constant glucose monitoring.

informed of the potential opportunities to join clinical trials at other sites. All participants received education on the symptoms of T1D onset and the disease management, which contributed to the prevention of DKA development at the onset of symptomatic T1D.

Unfortunately, data on potential reasons for reluctance or concerns about participating in and continuing the study were not collected, as well as mental health assessment was not performed; therefore there were no data enabling assessment of the direct impact of screening on individuals' mental wellbeing. This illustrates the shift in perception

of the T1D screening process and the movement towards a holistic and patient-centered model that incorporates psychological wellbeing assessment as a key component.

However, it is important to note that most participants – being First-degree relatives of individuals living with T1D – already had substantial disease awareness and understanding, which may have influenced how they perceived and accepted the final diagnosis. Nonetheless, any individual in need of psychological support was offered assistance from a qualified psychologist at the Medical University of Silesia site.




Fig. 2. Classification of screened individuals according to autoantibody status

T1D – type 1 diabetes; GAD65 – autoantibodies to glutamic acid decarboxylase 65; IAA – autoantibodies to insulin; IA-2A – autoantibodies to tyrosine phosphatase-like protein; ZnT8 – autoantibodies to zinc transporter 8; 1AA group – individuals with 1 autoantibody present; DKA – diabetic ketoacidosis.

Results

Among 817 first-degree relatives of individuals with T1D, 7.96% (n = 65) tested positive for at least 1 autoantibody. Of these, 5.87% (n = 48) had a single autoantibody, corresponding to an estimated 15% risk of developing T1D within 15 years, with most progression occurring within 2 years of seroconversion. The remaining 2.08% (n = 17) had ≥2 autoantibodies, associated with a 44% risk of progression to stage 3 T1D within 5 years and an almost 100% lifetime risk.^{5,6,10}

Among the 48 individuals with a single autoantibody, 6 (12.5%) subsequently reverted to seronegative status. In 5 cases the autoantibody was GAD65, and in 1 case IAA. These individuals represented a wide age range (3, 8, 15, 17, 34, and 39 years), with no discernible pattern related to age at seroreversion. Four were siblings and 2 were parents of a child with T1D.

Additionally, 15 of the 48 participants with a single autoantibody were initially recruited as PIR rather than UFM. At that time, eligibility for follow-up required the presence

of at least 2 autoantibodies. Since these participants did not meet the follow-up criteria and no subsequent data regarding their autoantibody status were available, the true incidence of transient autoantibody positivity may be underestimated. Over the course of the study, 2 children progressed to symptomatic stage 3 T1D. In both cases, DKA was not observed at the time of onset (see Fig. 2 for details).

Autoantibody identification stratified by age

Individuals were divided into 5 age groups: 0–9, 10–23, 24–36, 37–40, and 41–45 years, each accounting for approx. 20% of the total PIR and UFM study population (n = 817). The largest group was the 41–45 age range (184 participants, 22.52%), while the least populous group was the 37–40 age range (146 participants, 17.75%) (Table 4).

Most participants with positive autoantibodies had only 1 autoantibody (73.85% of the total AA+ group; n = 48). Seventeen (26.15%) were found having 2 or more autoantibodies, with 8 (12.31%) having 2 autoantibodies, 6 (9.23%)

Table 4. Age categories for study participants

Age range [years]	Number of people in this age range	% of all participants (PIR and UFM; 817)	Number of people with AA+	% of AA+ within this age category	% of AA+ in this age group out of all AA (+)
1–9	163	19.95%	12	7.36%	18.46%
10–23	163	19.95%	18	11.04%	27.69%
24–36	162	19.83%	11	6.79%	16.92%
37–40	145	17.75%	13	8.97%	20.00%
41–45	184	22.52%	11	5.98%	16.92%

PIR – People at Increased Risk; UFM – Unaffected Family Member; AA – autoantibodies.




Fig. 3. Age-group distribution (%) of individuals by autoantibody count

having 3 autoantibodies and 3 (4.62%) with 4 autoantibodies. The majority of AA+ individuals were aged 10–23, accounting for 27.69% of all AA+ (18 of 65).

Consequently, 11.04% (18 of 163) of participants in this age group had at least 1 autoantibody, while the percentage for other age categories ranged from 5.98% to 8.97%. The 10–23 age group also had the highest prevalence of 2 autoantibodies (2.5%, $n = 4$) and 4 autoantibodies (1.2%, $n = 2$). There were 2 individuals with 3 autoantibodies (1.2%, $n = 2$) both for the 10–23 and 24–36 age category. People between the age 10–23 accounted for 50.00% ($n = 4$) of cases with 2 autoantibodies, for 33.33% ($n = 2$) with 3 autoantibodies and for 66.67% ($n = 2$) with 4 autoantibodies.

There is a predominance of younger individuals with 2 autoantibodies, which can be observed in Fig. 3. However, this pattern was not observed in the group with only 1 autoantibody. In contrast, participants aged 37–45 accounted for approx. 46% ($n=22$) of the 1AA group. Additionally, 20.83% ($n = 10$) of individuals with 1 autoantibody were between 10 and 23 years old, while 18.75% ($n = 9$) were aged 24–36. The lowest percent of people with 1 autoantibody was in the 0–9 age group (14.58%, $n = 7$). Single-autoantibody cases demonstrated a more balanced age-profile than cases with 2 autoantibodies; however, the aspect of a very small sample must be taken into consideration (Fig. 3). In the 37–40 age group, 7.59% of participants had 1 autoantibody, while the percentage for 2 autoantibodies and 3 autoantibodies was 0.69% in both cases, and none was found having 4 autoantibodies. Although there is a slight predominance of positive

autoantibodies in younger individuals, it is important to note that autoantibodies were detected in all age groups, supporting the rationale for including adults (>18 years) in T1D screening programs.

Figure 4 shows that the occurrence of specific autoantibodies is in overall similar across age groups. However, 66.7% ($n = 6$) of IA-2A cases were in the 10–23 age group, while this group accounted for 25% ($n = 3$ for ZnT8) to 35% ($n = 10$ for IAA) of cases for other autoantibodies. Certainly, due to the small sample size, no firm conclusions can be drawn at this point.

Autoantibody identification stratified by sex

As noted, 65 participants (7.96%) had at least 1 autoantibody (Fig. 2). GAD65 was the most common, found in 69.23% ($n = 45$) of all AA+ cases and 5.51% of all screened (Fig. 5). IAA was found in 43.08% ($n = 28$; 3.43% of UFM and PIR), followed by ZnT8 in 18.46% ($n = 12$; 1.47% of UFM and PIR) and IA-2A in 13.85% ($n = 9$; 1.10% of UFM and PIR).

The stratification of autoantibodies by sex (Fig. 6) mirrored the overall incidence, with women marginally higher (53.85%, $n = 35$) than men (46.15%, $n = 30$), which is consistent with the study's overall sex ratio (56.55% women). In general, 7.58% of women ($n = 35$) in the study had positive autoantibodies, compared to 8.45% ($n = 30$) of men. Therefore, although a greater number of women tested positive for autoantibodies, the detection rate relative to the number




Fig. 4. Age-group distribution (%) and number of individuals with a specific autoantibody

of participants was higher in men. Women also represented the majority of those with 1 autoantibody (60.42%, n = 29). In contrast, the majority of those with ≥2 autoantibodies were male: 62.50% (n = 5) for 2 autoantibodies, 66.67% (n = 4) for 3 autoantibodies and 66.67% (n = 2) for 4 autoantibodies. Despite predominance of women in the study, GAD65 incidence was similar: 5.19% (n = 24) in women and 5.92% (n = 21) in men. IAA was more frequent in men

(4.23%, n = 15) than women (2.81%, n = 13), while IA-2A was even 4 times more frequent in men (1.97%, n = 7) than women (0.43%, n = 2). Again, no definite conclusions can be drawn about the prevalence of specific autoantibodies across age groups due to the limited number of cases in each group.

Participants with 2 or more autoantibodies

Type 1 diabetes screening enables to identify individuals at an early stage of T1D. Those in stage 1 face a nearly 100% lifetime risk of progressing to stage 3 T1D.^{5,6,10,15} Given the importance of early detection and monitoring, data




Fig. 5. Distribution of specific autoantibodies identified among study participants




Fig. 6. Sex-based distribution (%) of individuals with a specific autoantibody

Table 5. Description of (2 or more AA+) group of study participants

Type of A	Prevalence of specific AA in $\geq 2AA$ (+) group	Number of detected AA to the total number of screened participants (817)	% of detected specific AA in (+) group to all 65 cases of AA (+)	% of detected specific AA in $\geq 2AA$ (+) group to all 17 cases of the 2AA (+) group
GAD65	16	1.96%	24.62%	94.12%
IAA	13	1.59%	20.00%	76.47%
IA-2A	9	1.10%	13.85%	52.94%
ZnT8	8	0.98%	12.31%	47.06%

AA – autoantibodies; ** 2AA (+) group – individuals with autoantibodies present; GAD65 – autoantibodies to glutamic acid decarboxylase 65; IAA – autoantibodies to insulin; IA-2A – autoantibodies to tyrosine phosphatase-like protein; ZnT8 – autoantibodies to zinc transporter 8.

Table 6. Autoantibodies combinations in the (2 or more AA+) group

GAD65	IAA	IA-2A	ZnT8	Frequency of given AA configuration in the group of study participants with (+)
+	+	–	+	4
+	+	–	–	4
+	+	+	+	3
+	–	+	–	3
+	+	+	–	2
–	–	+	+	1

AA – autoantibodies; ** 2AA (+) group – individuals with autoantibodies present; GAD65 – autoantibodies to glutamic acid decarboxylase 65; IAA – autoantibodies to insulin; IA-2A – autoantibodies to tyrosine phosphatase-like protein; ZnT8 – autoantibodies to zinc transporter 8.

for participants with multiple (2 or more) autoantibodies were analyzed separately (Table 5).

Seventeen participants (1.96% of the UFM and PIR group, $n = 817$) had multiple (2 or more) autoantibodies, representing 26.15% of all those with AA+. These individuals were classified as stage 1 T1D, as all had normoglycemia, and back then no continuous glucose monitoring (CGM) was required for them.

In both the AA+ group and the $\geq 2AA$ group, GAD65 and IAA occurred with the highest prevalence. For people with ≥ 2 autoantibodies, IA-2A was 3rd most frequent (9 out of 17), while in the overall AA+ group, it was ZnT8.

Six out of the 17 participants with ≥ 2 autoantibodies were female, with age ranging from 1 to 37 years (1, 6, 11,

13, 35, 37). The remaining 11 participants were male, with age ranging from 2 to 40 years (2 ($n = 2$), 3, 10, 11 ($n = 2$), 12, 12, 15, 33, 40).

To observe the co-occurrence of autoantibodies and their combinations in the study participants, all configurations and their frequencies are presented in the Table 6.

Follow-up diagnoses of stage 3 T1D in study participants

Within this group, a 6-year-old girl and a 10-year-old boy progressed to stage 3 T1D, both without developing DKA at diagnosis (Table 7).

The 6-year-old girl tested positive for 2 autoantibodies – GAD65 and IAA – at screening visit and progressed to stage 3 T1D after 22 months. At her last follow-up visit, 53 days before clinical onset, there were no signs of dysglycemia (HbA1c: 36.64 mmol/mol). She began regular visits at the Diabetes Outpatient Department and, 21 months post-diagnosis, is being treated with insulin injections twice a day. Her current HbA1c is 5.2%, with a time in range (TIR) of 93%.

The 9-year-old boy, positive for GAD65, IAA and IA-2A at screening, progressed to stage 3 T1D within only 4.5 months. IA-2A presence, high autoantibody levels and high-affinity screening have been shown to predict rapid progression to clinical T1D.^{9,10} Similarly to the 6-year-old girl, his follow-up visit took place 50 days before disease onset and presented no dysglycemia (HbA1c: 36.62 mmol/mol). Now 13 years old, he attends follow-up visits, using

Table 7. Description of individuals diagnosed with type 1 diabetes (T1D) during the study

Variable	6-year-old girl	10-year-old boy
Family history	sibling living with T1D	sibling living with T1D
AA preset at screening	GAD65, IAA	GAD65, IAA, IA-2A
Time of diagnosis	22 months after screening visit	4.5 months after screening visit
DKA	no DKA at diagnosis	no DKA at diagnosis
HbA1c at last follow-up visit	36.64 mmol/mol (53 days before diagnosis)	36.62 mmol/mol (50 days before diagnosis)
Current data	10 years old, HbA1c 5.7%; TIR 93%, insulin injection twice a day	13 years old, HbA1c 7.4%, TIR 58%, insulin pump 0.8 u/h

GAD65 – autoantibodies to glutamic acid decarboxylase 65; IAA – autoantibodies to insulin; IA-2A – autoantibodies to tyrosine phosphatase-like protein; DKA – diabetic ketoacidosis; HbA1c – hemoglobin A1c (%); TIR – time in range (%).

an insulin pump (0.8 units/h), with a TIR of 58% and an HbA1c of 7.4%. At times, he may question or be reluctant to follow his treatment plan, which is not uncommon for individuals his age.

Autoantibody profiles stratified by family relationship

The largest group of participants were parents of individuals with T1D (60.59%, 495), followed by siblings (38.19%, 312) and children of parents with T1D (4.41%, 36). It is important to note that individuals may be counted more than once if they fit multiple categories. Among children with a parent diagnosed with T1D, 8.33% (3/36) were positive for at least 1 autoantibody, while for parents of children with T1D it was 7.27% (36/495). The highest percentage of autoantibodies was found in siblings, at 9.62% (30/312).

Among those with 1 autoantibody, 66.67% (n = 32) were parents of children with T1D, 35.42% (n = 17) were siblings and 4.17% (n = 2) were children of a parent with T1D. The highest incidence of 2 autoantibodies was found in siblings of individuals with T1D, who accounted for 75% (6 out of 8) of all individuals with 2 autoantibodies.

Three autoantibodies were only found in siblings (n = 4, 66.67%) and parents of children with T1D (n = 3, 50.00%), while 4 autoantibodies were observed exclusively in 3 individuals, all of whom were siblings of a person with T1D.

When examining autoantibody prevalence by the familial relationships, GAD65 was most common in both siblings and parents. Of the 45 individuals with positive GAD65, 53.33% were siblings and 48.89% were parents. Only 4.44% were children of parent with T1D. It is important to consider that individuals may have multiple familial connections to an individual with T1D.

Similarly, IAA was most often found in siblings (53.57%; n = 15) and parents of individuals with T1D (42.86%; n = 12). Interestingly, 88.9% (n = 9) of those with IA-2A were siblings and 11.10% (n = 1) were parents. No cases of IA-2A were observed in children of T1D parents. The same pattern was seen for ZnT8, which was found only in siblings (50.00%; n = 6) and parents (66.67%; n = 8).

Discussion

The Polish INNODIA cohort provides insight into T1D development risk in the first-degree relatives of people living with T1D. Among the 65 participants with autoantibodies, 73.8% (n = 48) had 1 positive autoantibody, with GAD65 and IAA being most common. Despite the smaller sample size (n = 817), the findings are consistent with the broader INNODIA dataset (n > 4,400) and with the Type 1 Diabetes TrialNet Pathway to Prevention Study (TN01), a USA-based consortium (n > 250,000), both

of which focus on screening first-degree relatives of individuals with T1D.^{10,16}

Although both studies were still ongoing as of 2022 and had not yet reported final results, they demonstrated similar patterns in autoantibody prevalence, with GAD65 and IAA being the most frequently observed.¹⁶ In the Polish INNODIA cohort, 7.96% of first-degree relatives tested positive for at least 1 autoantibody, compared to 5.00% in TrialNet TN01. The prevalence of ≥ 2 autoantibodies in the Polish cohort (2.08%) was comparable to that reported in the overall INNODIA (2.6%) and TrialNet TN01 (2.5%) studies.^{10,16}

These similarities suggest that autoantibody patterns in the Polish data align with those in larger international cohorts, though caution is needed due to the limited sample size. Despite differences in number of participants and regions, these studies indicate consistent T1D risk in first-degree relatives across populations. While Poland lacks a national T1D screening program, a study performed by the Medical University of Bialystok reported that 7.78% of 3,575 children screened had at least 1 autoantibody, with markedly higher prevalence of a single autoantibody (6.60%; n = 236) compared to multiple autoantibodies (1.17%, n = 42). It is important to note, however, that this study focused on children aged 1–9 years, a younger cohort than that examined in the INNODIA study, and included a broader population, not limited to first-degree relatives.¹⁷

Type 1 diabetes mellitus screening in clinical practice enables the detection of early-stage disease, reducing the incidence of DKA and facilitating enrollment in clinical trials for disease-modifying therapies. Early diagnosis through screening reduces DKA rates at onset to below 5%, whereas in Poland, 30–40% of children with newly diagnosed T1D present with DKA.^{5,15,18–20}

Prior screening, metabolic staging and education help eliminate clinical differences between individuals with and without a family history of T1D.^{18,21} In the Fr1da study, participants who did not receive early intervention – including education – had higher HbA1c levels and more frequent hospitalizations compared with those who did.⁷ Similarly, individuals with a family history had lower HbA1c levels (9.3% vs 10.6%) and fewer cases of severe ketonuria compared to those without a family history. These studies emphasize the importance of awareness and early detection through screening and proper education.⁸

In the Polish INNODIA study, most AA-positive individuals (73.8%, n = 48) presented with a single autoantibody. Although their risk of progressing to T1D is comparatively lower – with approx. 50% of children showing transient positivity – they still require careful monitoring, particularly younger individuals and those within the first 2 years of seroconversion.⁶

Type 1 diabetes screening is a complex process, with various factors potentially influencing the decision to participate such as fear of positive result or inability to prevent T1D.^{22,23} To improve participation, it is essential to address

the emotional challenge associated with screening and to provide appropriate psychological support, particularly for individuals experiencing anxiety about the results. Providing support and educating individuals on T1D, its autoimmune causes, symptoms, and the importance of early detection can reduce stress and encourage continued involvement. A balanced approach combining medical information and emotional support is a key to motivating participation.

Limitations of the study

In Poland, over 1/3 of children newly diagnosed with T1D present with DKA.^{18,19} The INNODIA study, which focused on first-degree relatives of individuals with T1D, does not fully represent the general population. Accordingly, broader screening and early detection initiatives should be implemented to encompass the general public. A proactive approach, emphasizing early recognition of symptoms and timely support, should be incorporated into care protocols for individuals at the earliest stages of T1D. Additional analyses, such as the influence of birth order and sibling sex, may provide further insights, although the relatively small sample size in this study limits the reliability of such conclusions.

Conclusions

Analysis of the Polish INNODIA results reveals a similar occurrence of autoantibodies in first-degree relatives of people with T1D when compared to other European countries. Early detection of T1D is an evolving initiative that offers valuable medical care not only to relatives of people living with T1D but also to the broader population.

Although the process is complex and optimal strategies are still under development, substantial progress has been achieved since the early phases of the INNODIA screening program. These advances provide a solid foundation for the potential implementation of national screening initiatives, with the ultimate goal of improving patient care.

Data Availability Statement

The datasets supporting the findings of the current study are openly available in the Zenodo repository at <https://doi.org/10.5281/zenodo.15574493>.

Consent for publication

Not applicable.

Use of AI and AI-assisted technologies

Not applicable.

ORCID iDs

Magdalena Małachowska  <https://orcid.org/0009-0008-2147-4316>
 Kamil Kosiorowski  <https://orcid.org/0009-0009-4020-2188>
 Eliza Skala-Zamorowska  <https://orcid.org/0000-0002-9140-3686>
 Przemysław Jarosz-Chobot  <https://orcid.org/0000-0002-1120-0994>
 Sebastian Seget  <https://orcid.org/0000-0002-1917-6351>
 Ewa Rusak  <https://orcid.org/0000-0002-4422-7704>
 Halla Kamińska  <https://orcid.org/0000-0003-0960-8365>
 Grażyna Deja  <https://orcid.org/0000-0001-6779-4966>
 Aleksandra Pyziak-Skupień  <https://orcid.org/0000-0002-7520-8506>

References

1. Tekielak A, Otto-Buczowska E, Rusak E. Less common forms of diabetes in young population. *Pediatr Endocrinol Diabetes Metab.* 2024; 30(1):29–35. doi:10.5114/pedm.2024.136279
2. Bauer W, Gyenesei A, Krętownski A. The multifactorial progression from the islet autoimmunity to type 1 diabetes in children. *Int J Mol Sci.* 2021;22(14):7493. doi:10.3390/ijms22147493
3. Tatovic D, Narendran P, Dayan CM. A perspective on treating type 1 diabetes mellitus before insulin is needed. *Nat Rev Endocrinol.* 2023; 19(6):361–370. doi:10.1038/s41574-023-00816-5
4. Quinn LM, Dias RP, Bidder C, et al. Presentation and characteristics of children with screen-detected type 1 diabetes: Learnings from the ELSA general population pediatric screening study. *BMJ Open Diab Res Care.* 2024;12(5):e004480. doi:10.1136/bmjdr-2024-004480
5. Haller MJ, Bell KJ, Besser REJ, et al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes. *Horm Res Paediatr.* 2024;97(6):529–545. doi:10.1159/000543035
6. Phillip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. *Diabetes Care.* 2024;47(8):1276–1298. doi:10.2337/dci24-0042
7. Hummel S, Carl J, Friedl N, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. *Diabetologia.* 2023;66(9):1633–1642. doi:10.1007/s00125-023-05953-0
8. Bonifacio E, Coelho R, Ewald DA, et al. The efficacy of islet autoantibody screening with or without genetic pre-screening strategies for the identification of presymptomatic type 1 diabetes. *Diabetologia.* 2025;68(6):1101–1107. doi:10.1007/s00125-025-06408-4
9. European Commission. Translational approaches to disease modifying therapy of type 1 diabetes: An innovative approach towards understanding and arresting type 1 diabetes. Sofia ref. 115797. Brussels, Belgium: European Commission; 2015. doi:10.3030/115797
10. Sims EK, Besser REJ, Dayan C, et al. Screening for type 1 diabetes in the general population: A status report and perspective. *Diabetes.* 2022;71(4):610–623. doi:10.2337/dbi20-0054
11. Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. *Pediatr Diabetes.* 2018;19(3):346–353. doi:10.1111/pedi.12597
12. Dorman J, Steenkiste A, O'Leary L, McCarthy B, Lorenzen T, Foley T. Type 1 diabetes in offspring of parents with type 1 diabetes: The tip of an autoimmune iceberg? *Pediatr Diabetes.* 2000;1(1):17–22. doi:10.1034/j.1399-5448.2000.010104.x
13. Hoffmann L, Kohls M, Arnolds S, et al. EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents. *BMJ Open.* 2025;15(1):e088522. doi:10.1136/bmjopen-2024-088522
14. Marcovecchio ML, Hendriks AEJ, Delfin C, et al. The INNODIA Type 1 Diabetes Natural History Study: A European cohort of newly diagnosed children, adolescents and adults. *Diabetologia.* 2024;67(6):995–1008. doi:10.1007/s00125-024-06124-5
15. Simmons KM, Sims EK. Screening and prevention of type 1 diabetes: Where are we? *J Clin Endocrinol Metab.* 2023;108(12):3067–3079. doi:10.1210/clinem/dgad328
16. Battaglia M, Anderson MS, Buckner JH, et al. Understanding and preventing type 1 diabetes through the unique working model of TrialNet. *Diabetologia.* 2017;60(11):2139–2147. doi:10.1007/s00125-017-4384-2
17. Jamiolkowska-Sztabkowska M, Noiszewska K, Polkowska A, et al. Get ahead of the disease: Islet cell autoimmunity and preclinical phase of type 1 diabetes in general population of 1–9 year-old children in the north-eastern region of Poland: A summary of the first 18 months of the study. *Diabetes Obes Metab.* 2025;27(9):5108–5117. doi:10.1111/dom.16560

18. Pietrzak I, Michalak A, Seget S, et al. Diabetic ketoacidosis incidence among children with new-onset type 1 diabetes in Poland and its association with COVID-19 outbreak: Two-year cross-sectional national observation by PolPeDiab Study Group. *Pediatr Diabetes*. 2022;23(7): 944–955. doi:10.1111/pedi.13379
19. Rusak E, Seget S, Macherski M, Furgał N, Dys P, Jarosz-Chobot P. Has the COVID-19 pandemic affected the prevalence of diabetic ketoacidosis in Polish children with newly diagnosed type 1 diabetes? An example of the largest Polish pediatric diabetes center (Upper Silesia, Katowice, Poland). *Healthcare (Basel)*. 2022;10(2):348. doi:10.3390/healthcare10020348
20. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. *Lancet*. 2018; 391(10138):2449–2462. doi:10.1016/S0140-6736(18)31320-5
21. Neuman V, Piona C, Cudizio L, et al. Are we ready to screen for type 1 diabetes? A structured worldwide survey among healthcare providers involved in paediatric diabetes care. *Diabet Med*. 2024; 41(6):e15329. doi:10.1111/dme.15329
22. Scudder C, Townson J, Bowen-Morris J, et al. General population screening for type 1 diabetes using islet autoantibodies at the pre-school vaccination visit: A proof-of-concept study (the T1Early study). *Arch Dis Child*. 2024;109(10):812–817. doi:10.1136/archdischild-2023-326697
23. Kelly CS, Wolf WA, Cornelius EM, Peter ME, Chapman KS, Dunne JL. Insights into knowledge and attitudes about autoantibody screening from people affected by type 1 diabetes: A brief report. *Diabetes Ther*. 2024;15(10):2249–2261. doi:10.1007/s13300-024-01637-z